Upload
afifi-faridz-xanedia
View
1.293
Download
2
Tags:
Embed Size (px)
DESCRIPTION
about the tumor marker on the cancer progression and diagnosis
Citation preview
Cancer Biochemistry
Tumour marker
• Any substance that can be related to the presence or progress of a tumour.
• Hormones: human gonadotrophin (HCG) secreted by choriocarcinoma
• Enzymes: prostate specific antigen (PSA) in prostate carcinoma
• Tumour antigens: carcinoembryonic antigen (CEA) in colorectal carcinoma
The use of tumour markers
Monitoring treatment• Surgery, chemotherapy, radiotherapy
Assessing follow-up• To monitor the marker long after the levels have
appeared to stabilized
Diagnosis• Detection in blood, biopsy
Prognosis• To be of value in prognosis, the
concentration of the tumour marker in plasma should be correlate with tumour mass.
• Eg: HCG correlates well with the tumour mass in choriocarcinoma
• HCG and AFP correlate with the tumour mass in testicular teratoma
• Paraproteins correlate with the tumour mass in multiple myeloma.
Screening for the presence of disease• Specific high-risk population• Eg: hormone calcitonin, which is
increased in all patients with medullary carcinoma of thyroid, may be used to screen close relatives.
The important tumour markers:
• Alkaline phosphatase (ALP)• Lactate dehydrogenase (LDH)• Prostatic acid phosphatase (PAP)• Prostate specific antigen (PSA)• Human chorionic gonadotropin (HCG)• Alpha-fetoprotein (AFP)• Carcino-embryonic antigen (CEA)
• CA-15 : marker for breast carcinomas• CA-125 : marker for ovarian and
endometrial carcinoma• Calcitonin (secreted by cells of thyroid
gland. Increased in medullary tumour of thyroid gland)
*carcinoma: cancer arising from epithelial tissue.
sarcoma: cancer from connective tissue
• ALP- Primary or secondary liver cancer- Secondary bone cancer- Lung cancer- Cancer of GIT and ovary- Hodgkin’s disease
• PAP-malignant conditions: cancer of prostate,
multiple myeloma, osteogenic sarcoma.-benign conditions: prostatic hypertrophy
(BPH) or enlarged prostate, osteoporosis and hyperparathyroidism.
• PSA-superior marker for prostatic cancer.
• Human Chorionic Gonadotropin (HCG)-placental hormon. Synthesized by
syncytiotrophoblastic cells of placental villi.-choriocarcinoma. About 50% of cases of
choriocarcinoma follow hydatidiform mole pregnancy and HCG is used to screen these women.
-ideal tumour marker for diagnosing and monitoring gestational trophoblastic tumours and germ cell tumours of testes and ovary.
• Alpha-Feto Protein (AFP)-like CEA, AFP is another oncofetal antigen.
AFT is synthesized in liver, yolk sac and GI tract in fetal life and released into serum of fetus.
-AFP is the more specific and ideal tumour marker for primary carcinoma of the liver (hepatocellular carcinoma)
-serum AFP and HCG are best available tumour markers for germ cell type of tumours.
• Cancer antigen 125 (CA-125)-used for screening and diagnosis of ovarian
carcinoma-not specific for ovarian carcinoma
• CA 15-3 & CA-27.29- useful as tumour marker in breast carcinoma
• CA 19-9-useful as tumour marker in pancreatic cancer
and biliary tract cancers.
Hormones
• produced by many tumors• natural product or represent abnormal
synthesis• eg: insulin by islet cell tumor, calcitonin by
medullary thyroid carcinoma, catecholamines by pheochromocytoma
• ectopic hormones - ACTH and ADH by lung cancer